No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DYN240517C25000
- 2.70
- -0.60-18.18%
15min DelayClose May 17 15:59 ET
2.85High2.70Low
2.85Open3.30Pre Close6 Volume114 Open Interest25.00Strike Price1.68KTurnover631.89%IV1.97%PremiumMay 17, 2024Expiry Date2.68Intrinsic Value100Multiplier0DDays to Expiry0.02Time Value100Contract SizeAmericanOptions Type0.7804Delta0.0735Gamma8.58Leverage Ratio-3.1243Theta0.0001Rho6.70Eff Leverage0.0019Vega
Intraday
- 5D
- 1D
News
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Dyne Therapeutics Price Target Maintained With a $31.00/Share by Chardan Capital
Dyne Therapeutics Price Target Maintained With a $31.00/Share by Chardan Capital
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dyne Therapeutics, Inc. (NASDAQ:DYN) Is Largely Controlled by Institutional Shareholders Who Own 53% of the Company
Key Insights Significantly high institutional ownership implies Dyne Therapeutics' stock price is sensitive to their trading actions 51% of the business is held by the top 10 shareholders Insider
Express News | Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
Comments
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
5
John Cox's appointment, with his vast biotech industry and rare disease commercialization experience, is viewed positively for Dyne Therapeutics. His leadership is anticipated to enhance the company's clinical programs and pipeline, and build more capabilities as Dyne continues to create stakeholder value.
1
Recent insider share sale at current price raises slight concern. Lack of insider buying and low level of insider ownership over the past year do not inspire excitement about the stock.
2
Read more